Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
At Creative Biolabs, our advanced platforms enable us to deliver comprehensive antibody solutions that meet our clients' specific needs, thereby supporting your meaningful research and discovery efforts globally. We strive to empower our clients to achieve their scientific goals quickly and precisely by prioritizing exceptional value and providing unparalleled technical support. Trust Creative Biolabs to be your partner in making ground-breaking research discoveries.
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase belonging to the insulin receptor superfamily. The activation of this gene is crucial in the pathogenesis of various human malignancies, including anaplastic large-cell lymphoma, neuroblastoma, inflammatory myofibroblastic tumors, and lung cancer. Given its limited expression in adult tissues, targeting ALK in cancer treatment is promising, with the expectation of minimal toxic effects. This makes ALK an attractive therapeutic target for developing novel cancer treatments.
Anaplastic lymphoma kinase; CD246; NBLST3; anaplastic lymphoma receptor tyrosine kinase; ALK receptor tyrosine kinase; ALK (gene); anaplastic lymphoma kinase (Ki-1); Ki-1; NBLST3; Tcrz ALK CD246; NBLST3 ALK receptor tyrosine kinase ALK tyrosine kinase receptor.
Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins
Intracellular, Membrane (different isoforms)
Group enriched (Oligodendrocyte precursor cells, Inhibitory neurons)
Not detected in immune cells
Cell line enriched (SH-SY5Y)
Homodimer; homodimerizes following heparin- and ligand-binding (PubMed:16317043, PubMed:25605972, PubMed:34646012, PubMed:34819673). Interacts with CBL, IRS1, PIK3R1 and PLCG1 (PubMed:15226403). Interacts with FRS2 and SHC1 (PubMed:15226403, PubMed:16878150, PubMed:17274988). Interacts with PTN and MDK (PubMed:11278720, PubMed:12122009).
Kinase, Receptor, Transferase, Tyrosine-protein kinase
Leveraging our advanced antibody engineering platform in Shirley, we have developed a series of innovative and effective anti-ALK recombinant antibody products. Meanwhile, we provide these premium products for clients around the world to aid your challenging antibody discovery and development projects. Please click the provided link to get more details of your interested products.
Cat. No. | Product Name | Target Species | Host Species | Applications |
HPAB-1826LY | Mouse Anti-ALK Recombinant Antibody | Human, Mouse | Mouse IgG | ELISA, WB, FC |
HPAB-1825LY | Mouse Anti-ALK Recombinant Antibody | Human, Mouse | Mouse IgG | ELISA, WB, FC |
HPAB-1824LY | Mouse Anti-ALK Recombinant Antibody | Human, Mouse | Mouse IgG | ELISA, WB, FC |
HPAB-1823LY | Mouse Anti-ALK Recombinant Antibody | Human, Mouse | Mouse IgG | ELISA, WB, FC |
HPAB-1822LY | Mouse Anti-ALK Recombinant Antibody | Human, Mouse | Mouse IgG | FC, WB, ELISA, Inhib, FuncS |
NS-004CN | Human Anti-ALK Recombinant Antibody (clone ESBA521) | Human | Human IgG | ELISA, WB, FuncS |
We are dedicated to empowering the biopharmaceutical community by fostering innovation in research and development with top-tier product quality and outstanding support. Customer satisfaction is at the core of our operations, which is why we meticulously maintain a robust quality management system. This ensures that our products consistently meet and often surpass industry standards. By doing so, we enhance the efficiency of the drug development process and provide exceptional value to our customers.
Our advanced serum-free mammalian cell expression platform provides an end-to-end solution from gene synthesis to the scalable production of high-quality anti-ALK recombinant antibodies. With over five years devoted to refining our processes, we offer cost-efficient and swift production, ensuring rapid delivery of various antibody quantities.
Featured Anti-ALK Recombinant Antibody Production Platforms
Fig.1 Milligram-scale anti-ALK recombinant antibody production.
Fig.2 Gram-scale anti-ALK recombinant antibody production.
Creative Biolabs prides itself on providing a wide array of cutting-edge recombinant antibodies tailored for researchers. Our portfolio of anti-ALK antibodies is available in multiple formats, including full-length, Fab, and scFv. Backed by our profound knowledge and years of experience in antibody engineering, we are well-equipped to offer bespoke solutions that cater to your unique research requirements.
Fig.3 Full-Length Anti-ALK Recombinant Antibody Production and Modalities
Table 1. ALK-targeted drug information.
Company | Highest Phase | Classification | Condition |
Celldex Therapeutics (Originator) | Preclinical |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) |
Neuroblastoma |
Celldex Therapeutics (Originator) | Preclinical |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) |
Neuroblastoma |
Universita degli Studi di Torino (Originator) | Preclinical |
Cancer Immunotherapy Cancer Vaccines DNA Vaccines |
Neuroblastoma |
AIST (Originator) | Preclinical |
Oligopeptides, less than 10 AA Peptide-Drug Conjugates |
Cancer |
Co-D Therapeutics University of Wisconsin-Madison (Originator) Wisconsin Alumni Research Foundation (Originator) |
Preclinical |
Fixed-Dose Combinations Micelles Microparticles Natural Products Rapamycins Taxanes |
Angiosarcoma Cancer, breast Cancer, lung (non-small cell) (NSCLC) |
CovX (Originator) | Preclinical | Immunoconjugates | Cancer, breast |
Istituto Giannina Gaslini (Originator) | Preclinical |
Nanoparticles Small Interfering RNA (SiRNAs) |
Neuroblastoma |
Kuur Therapeutics Novartis (Originator) |
Preclinical |
Cancer Immunotherapy Monoclonal Antibodies |
Cancer Glioblastoma |
Children's Hospital of Philadelphia (Originator) University of Pittsburgh (Originator) |
Biological Testing |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) |
Neuroblastoma |
Children's Hospital of Philadelphia (Originator) University of Pittsburgh (Originator) |
Biological Testing |
Bispecific Antibody Fusions Cancer Immunotherapy Fc Fusion Proteins Polypeptides, from 41 AA Single-Chain V-Domain Antibody Fragment (scFv) Single-Domain Antibodies |
Neuroblastoma |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
If you would like to learn more about our anti-ALK recombinant antibody products, please feel free to get in touch with us at your convenience.